Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Conditions

• Castleman's Disease (CD)
• Idiopathic Multicentric Castleman's Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Ruxolitinib — DRUG
  Participants will take the study drug in a tablet form, by mouth, every day for the next year, as long as it is helping with their disease and not causing unacceptable side effects.

Study Details

The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.

Key Dates

Start date

Dec 18, 2025

Status verified

Apr 2026

Primary completion

Jul 31, 2028

Completion

Dec 31, 2028

Study Design

Enrollment

14 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Other: Ruxolitinib
  This is an open-label study so all patients will be assigned to the same interventional arm and given ruxolitinib

Primary Outcome Measure

The proportion of participants achieving a positive Clinical Benefit Response (CBR) response at 12 months ± 1 month. Assessments at 12 months ± 1 month. will be compared to those at the baseline visit [ Time Frame: 12 months ± 1 month ]

Central Contacts

• Bridget Austin, MS
  267-586-9977
  [email protected]

Locations (1)

Find similar trials in Philadelphia, PA